Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer
Background It remains unclear whether total gastrectomy is necessary for patients with proximal T2/T3 gastric cancer. To explore the oncological safety of proximal gastrectomy for proximal T2/T3 gastric cancer, in this study, we evaluated the metastatic rates in and the therapeutic effect of dissect...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Yura, Masahiro [verfasserIn] Yoshikawa, Takaki [verfasserIn] Otsuki, Sho [verfasserIn] Yamagata, Yukinori [verfasserIn] Morita, Shinji [verfasserIn] Katai, Hitoshi [verfasserIn] Nishida, Toshirou [verfasserIn] Yoshiaki, Takaki [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Gastric Cancer - Springer-Verlag, 2002, 22(2019), 5 vom: 18. Feb., Seite 1029-1035 |
|---|---|
| Übergeordnetes Werk: |
volume:22 ; year:2019 ; number:5 ; day:18 ; month:02 ; pages:1029-1035 |
| Links: |
|---|
| DOI / URN: |
10.1007/s10120-019-00938-8 |
|---|
| Katalog-ID: |
SPR009350497 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR009350497 | ||
| 003 | DE-627 | ||
| 005 | 20201124064157.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201005s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10120-019-00938-8 |2 doi | |
| 035 | |a (DE-627)SPR009350497 | ||
| 035 | |a (SPR)s10120-019-00938-8-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yura, Masahiro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background It remains unclear whether total gastrectomy is necessary for patients with proximal T2/T3 gastric cancer. To explore the oncological safety of proximal gastrectomy for proximal T2/T3 gastric cancer, in this study, we evaluated the metastatic rates in and the therapeutic effect of dissection of key distal lymph node stations that are usually excluded in proximal gastrectomy. Methods In this study, we examined 202 patients seen between January 2000 and December 2012, who underwent total gastrectomy with lymph node dissection (D1/D1+/D2; 2/17/183) and was pathologically diagnosed as T2/T3 gastric cancer exclusively located in the upper third of the stomach. The theoretical therapeutic necessity of dissecting lymph nodes at each lymph node station was evaluated based on the therapeutic index calculated by multiplying the frequency of metastasis at each station and the 5-year survival rate of patients with metastasis to that station. Results The 5-year overall survival rate (95% confidence interval) was 72.9% (65.5–80.3). The metastatic rates at #4d and #12a were very low (0.99% and 0.006%, respectively), and those at #5 and #6 were zero, and therapeutic indices for #4d, #5, #6 and #12a were zero. On the other hand, the most frequent metastatic station was #3, followed by #1, #2 and #7 (overall metastatic rate > 12%), which was consistent with the order of the therapeutic indices. Conclusions Considering the nodal stations that need to be dissected, proximal gastrectomy would be the choice and oncologically safe for patients with T2/T3 proximal gastric cancer. | ||
| 650 | 4 | |a Proximal gastrectomy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Proximal gastric cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Therapeutic effect |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Yoshikawa, Takaki |e verfasserin |4 aut | |
| 700 | 1 | |a Otsuki, Sho |e verfasserin |4 aut | |
| 700 | 1 | |a Yamagata, Yukinori |e verfasserin |4 aut | |
| 700 | 1 | |a Morita, Shinji |e verfasserin |4 aut | |
| 700 | 1 | |a Katai, Hitoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Nishida, Toshirou |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshiaki, Takaki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastric Cancer |d Springer-Verlag, 2002 |g 22(2019), 5 vom: 18. Feb., Seite 1029-1035 |w (DE-627)SPR009286586 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2019 |g number:5 |g day:18 |g month:02 |g pages:1029-1035 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10120-019-00938-8 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2019 |e 5 |b 18 |c 02 |h 1029-1035 | ||
| author_variant |
m y my t y ty s o so y y yy s m sm h k hk t n tn t y ty |
|---|---|
| matchkey_str |
yuramasahiroyoshikawatakakiotsukishoyama:2019----:nooiasftopoiagsrcoyottpo |
| hierarchy_sort_str |
2019 |
| publishDate |
2019 |
| allfields |
10.1007/s10120-019-00938-8 doi (DE-627)SPR009350497 (SPR)s10120-019-00938-8-e DE-627 ger DE-627 rakwb eng Yura, Masahiro verfasserin aut Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background It remains unclear whether total gastrectomy is necessary for patients with proximal T2/T3 gastric cancer. To explore the oncological safety of proximal gastrectomy for proximal T2/T3 gastric cancer, in this study, we evaluated the metastatic rates in and the therapeutic effect of dissection of key distal lymph node stations that are usually excluded in proximal gastrectomy. Methods In this study, we examined 202 patients seen between January 2000 and December 2012, who underwent total gastrectomy with lymph node dissection (D1/D1+/D2; 2/17/183) and was pathologically diagnosed as T2/T3 gastric cancer exclusively located in the upper third of the stomach. The theoretical therapeutic necessity of dissecting lymph nodes at each lymph node station was evaluated based on the therapeutic index calculated by multiplying the frequency of metastasis at each station and the 5-year survival rate of patients with metastasis to that station. Results The 5-year overall survival rate (95% confidence interval) was 72.9% (65.5–80.3). The metastatic rates at #4d and #12a were very low (0.99% and 0.006%, respectively), and those at #5 and #6 were zero, and therapeutic indices for #4d, #5, #6 and #12a were zero. On the other hand, the most frequent metastatic station was #3, followed by #1, #2 and #7 (overall metastatic rate > 12%), which was consistent with the order of the therapeutic indices. Conclusions Considering the nodal stations that need to be dissected, proximal gastrectomy would be the choice and oncologically safe for patients with T2/T3 proximal gastric cancer. Proximal gastrectomy (dpeaa)DE-He213 Proximal gastric cancer (dpeaa)DE-He213 Therapeutic effect (dpeaa)DE-He213 Yoshikawa, Takaki verfasserin aut Otsuki, Sho verfasserin aut Yamagata, Yukinori verfasserin aut Morita, Shinji verfasserin aut Katai, Hitoshi verfasserin aut Nishida, Toshirou verfasserin aut Yoshiaki, Takaki verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 22(2019), 5 vom: 18. Feb., Seite 1029-1035 (DE-627)SPR009286586 nnns volume:22 year:2019 number:5 day:18 month:02 pages:1029-1035 https://dx.doi.org/10.1007/s10120-019-00938-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 22 2019 5 18 02 1029-1035 |
| spelling |
10.1007/s10120-019-00938-8 doi (DE-627)SPR009350497 (SPR)s10120-019-00938-8-e DE-627 ger DE-627 rakwb eng Yura, Masahiro verfasserin aut Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background It remains unclear whether total gastrectomy is necessary for patients with proximal T2/T3 gastric cancer. To explore the oncological safety of proximal gastrectomy for proximal T2/T3 gastric cancer, in this study, we evaluated the metastatic rates in and the therapeutic effect of dissection of key distal lymph node stations that are usually excluded in proximal gastrectomy. Methods In this study, we examined 202 patients seen between January 2000 and December 2012, who underwent total gastrectomy with lymph node dissection (D1/D1+/D2; 2/17/183) and was pathologically diagnosed as T2/T3 gastric cancer exclusively located in the upper third of the stomach. The theoretical therapeutic necessity of dissecting lymph nodes at each lymph node station was evaluated based on the therapeutic index calculated by multiplying the frequency of metastasis at each station and the 5-year survival rate of patients with metastasis to that station. Results The 5-year overall survival rate (95% confidence interval) was 72.9% (65.5–80.3). The metastatic rates at #4d and #12a were very low (0.99% and 0.006%, respectively), and those at #5 and #6 were zero, and therapeutic indices for #4d, #5, #6 and #12a were zero. On the other hand, the most frequent metastatic station was #3, followed by #1, #2 and #7 (overall metastatic rate > 12%), which was consistent with the order of the therapeutic indices. Conclusions Considering the nodal stations that need to be dissected, proximal gastrectomy would be the choice and oncologically safe for patients with T2/T3 proximal gastric cancer. Proximal gastrectomy (dpeaa)DE-He213 Proximal gastric cancer (dpeaa)DE-He213 Therapeutic effect (dpeaa)DE-He213 Yoshikawa, Takaki verfasserin aut Otsuki, Sho verfasserin aut Yamagata, Yukinori verfasserin aut Morita, Shinji verfasserin aut Katai, Hitoshi verfasserin aut Nishida, Toshirou verfasserin aut Yoshiaki, Takaki verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 22(2019), 5 vom: 18. Feb., Seite 1029-1035 (DE-627)SPR009286586 nnns volume:22 year:2019 number:5 day:18 month:02 pages:1029-1035 https://dx.doi.org/10.1007/s10120-019-00938-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 22 2019 5 18 02 1029-1035 |
| allfields_unstemmed |
10.1007/s10120-019-00938-8 doi (DE-627)SPR009350497 (SPR)s10120-019-00938-8-e DE-627 ger DE-627 rakwb eng Yura, Masahiro verfasserin aut Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background It remains unclear whether total gastrectomy is necessary for patients with proximal T2/T3 gastric cancer. To explore the oncological safety of proximal gastrectomy for proximal T2/T3 gastric cancer, in this study, we evaluated the metastatic rates in and the therapeutic effect of dissection of key distal lymph node stations that are usually excluded in proximal gastrectomy. Methods In this study, we examined 202 patients seen between January 2000 and December 2012, who underwent total gastrectomy with lymph node dissection (D1/D1+/D2; 2/17/183) and was pathologically diagnosed as T2/T3 gastric cancer exclusively located in the upper third of the stomach. The theoretical therapeutic necessity of dissecting lymph nodes at each lymph node station was evaluated based on the therapeutic index calculated by multiplying the frequency of metastasis at each station and the 5-year survival rate of patients with metastasis to that station. Results The 5-year overall survival rate (95% confidence interval) was 72.9% (65.5–80.3). The metastatic rates at #4d and #12a were very low (0.99% and 0.006%, respectively), and those at #5 and #6 were zero, and therapeutic indices for #4d, #5, #6 and #12a were zero. On the other hand, the most frequent metastatic station was #3, followed by #1, #2 and #7 (overall metastatic rate > 12%), which was consistent with the order of the therapeutic indices. Conclusions Considering the nodal stations that need to be dissected, proximal gastrectomy would be the choice and oncologically safe for patients with T2/T3 proximal gastric cancer. Proximal gastrectomy (dpeaa)DE-He213 Proximal gastric cancer (dpeaa)DE-He213 Therapeutic effect (dpeaa)DE-He213 Yoshikawa, Takaki verfasserin aut Otsuki, Sho verfasserin aut Yamagata, Yukinori verfasserin aut Morita, Shinji verfasserin aut Katai, Hitoshi verfasserin aut Nishida, Toshirou verfasserin aut Yoshiaki, Takaki verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 22(2019), 5 vom: 18. Feb., Seite 1029-1035 (DE-627)SPR009286586 nnns volume:22 year:2019 number:5 day:18 month:02 pages:1029-1035 https://dx.doi.org/10.1007/s10120-019-00938-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 22 2019 5 18 02 1029-1035 |
| allfieldsGer |
10.1007/s10120-019-00938-8 doi (DE-627)SPR009350497 (SPR)s10120-019-00938-8-e DE-627 ger DE-627 rakwb eng Yura, Masahiro verfasserin aut Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background It remains unclear whether total gastrectomy is necessary for patients with proximal T2/T3 gastric cancer. To explore the oncological safety of proximal gastrectomy for proximal T2/T3 gastric cancer, in this study, we evaluated the metastatic rates in and the therapeutic effect of dissection of key distal lymph node stations that are usually excluded in proximal gastrectomy. Methods In this study, we examined 202 patients seen between January 2000 and December 2012, who underwent total gastrectomy with lymph node dissection (D1/D1+/D2; 2/17/183) and was pathologically diagnosed as T2/T3 gastric cancer exclusively located in the upper third of the stomach. The theoretical therapeutic necessity of dissecting lymph nodes at each lymph node station was evaluated based on the therapeutic index calculated by multiplying the frequency of metastasis at each station and the 5-year survival rate of patients with metastasis to that station. Results The 5-year overall survival rate (95% confidence interval) was 72.9% (65.5–80.3). The metastatic rates at #4d and #12a were very low (0.99% and 0.006%, respectively), and those at #5 and #6 were zero, and therapeutic indices for #4d, #5, #6 and #12a were zero. On the other hand, the most frequent metastatic station was #3, followed by #1, #2 and #7 (overall metastatic rate > 12%), which was consistent with the order of the therapeutic indices. Conclusions Considering the nodal stations that need to be dissected, proximal gastrectomy would be the choice and oncologically safe for patients with T2/T3 proximal gastric cancer. Proximal gastrectomy (dpeaa)DE-He213 Proximal gastric cancer (dpeaa)DE-He213 Therapeutic effect (dpeaa)DE-He213 Yoshikawa, Takaki verfasserin aut Otsuki, Sho verfasserin aut Yamagata, Yukinori verfasserin aut Morita, Shinji verfasserin aut Katai, Hitoshi verfasserin aut Nishida, Toshirou verfasserin aut Yoshiaki, Takaki verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 22(2019), 5 vom: 18. Feb., Seite 1029-1035 (DE-627)SPR009286586 nnns volume:22 year:2019 number:5 day:18 month:02 pages:1029-1035 https://dx.doi.org/10.1007/s10120-019-00938-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 22 2019 5 18 02 1029-1035 |
| allfieldsSound |
10.1007/s10120-019-00938-8 doi (DE-627)SPR009350497 (SPR)s10120-019-00938-8-e DE-627 ger DE-627 rakwb eng Yura, Masahiro verfasserin aut Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background It remains unclear whether total gastrectomy is necessary for patients with proximal T2/T3 gastric cancer. To explore the oncological safety of proximal gastrectomy for proximal T2/T3 gastric cancer, in this study, we evaluated the metastatic rates in and the therapeutic effect of dissection of key distal lymph node stations that are usually excluded in proximal gastrectomy. Methods In this study, we examined 202 patients seen between January 2000 and December 2012, who underwent total gastrectomy with lymph node dissection (D1/D1+/D2; 2/17/183) and was pathologically diagnosed as T2/T3 gastric cancer exclusively located in the upper third of the stomach. The theoretical therapeutic necessity of dissecting lymph nodes at each lymph node station was evaluated based on the therapeutic index calculated by multiplying the frequency of metastasis at each station and the 5-year survival rate of patients with metastasis to that station. Results The 5-year overall survival rate (95% confidence interval) was 72.9% (65.5–80.3). The metastatic rates at #4d and #12a were very low (0.99% and 0.006%, respectively), and those at #5 and #6 were zero, and therapeutic indices for #4d, #5, #6 and #12a were zero. On the other hand, the most frequent metastatic station was #3, followed by #1, #2 and #7 (overall metastatic rate > 12%), which was consistent with the order of the therapeutic indices. Conclusions Considering the nodal stations that need to be dissected, proximal gastrectomy would be the choice and oncologically safe for patients with T2/T3 proximal gastric cancer. Proximal gastrectomy (dpeaa)DE-He213 Proximal gastric cancer (dpeaa)DE-He213 Therapeutic effect (dpeaa)DE-He213 Yoshikawa, Takaki verfasserin aut Otsuki, Sho verfasserin aut Yamagata, Yukinori verfasserin aut Morita, Shinji verfasserin aut Katai, Hitoshi verfasserin aut Nishida, Toshirou verfasserin aut Yoshiaki, Takaki verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 22(2019), 5 vom: 18. Feb., Seite 1029-1035 (DE-627)SPR009286586 nnns volume:22 year:2019 number:5 day:18 month:02 pages:1029-1035 https://dx.doi.org/10.1007/s10120-019-00938-8 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 22 2019 5 18 02 1029-1035 |
| language |
English |
| source |
Enthalten in Gastric Cancer 22(2019), 5 vom: 18. Feb., Seite 1029-1035 volume:22 year:2019 number:5 day:18 month:02 pages:1029-1035 |
| sourceStr |
Enthalten in Gastric Cancer 22(2019), 5 vom: 18. Feb., Seite 1029-1035 volume:22 year:2019 number:5 day:18 month:02 pages:1029-1035 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Proximal gastrectomy Proximal gastric cancer Therapeutic effect |
| isfreeaccess_bool |
false |
| container_title |
Gastric Cancer |
| authorswithroles_txt_mv |
Yura, Masahiro @@aut@@ Yoshikawa, Takaki @@aut@@ Otsuki, Sho @@aut@@ Yamagata, Yukinori @@aut@@ Morita, Shinji @@aut@@ Katai, Hitoshi @@aut@@ Nishida, Toshirou @@aut@@ Yoshiaki, Takaki @@aut@@ |
| publishDateDaySort_date |
2019-02-18T00:00:00Z |
| hierarchy_top_id |
SPR009286586 |
| id |
SPR009350497 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR009350497</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20201124064157.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10120-019-00938-8</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR009350497</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10120-019-00938-8-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Yura, Masahiro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background It remains unclear whether total gastrectomy is necessary for patients with proximal T2/T3 gastric cancer. To explore the oncological safety of proximal gastrectomy for proximal T2/T3 gastric cancer, in this study, we evaluated the metastatic rates in and the therapeutic effect of dissection of key distal lymph node stations that are usually excluded in proximal gastrectomy. Methods In this study, we examined 202 patients seen between January 2000 and December 2012, who underwent total gastrectomy with lymph node dissection (D1/D1+/D2; 2/17/183) and was pathologically diagnosed as T2/T3 gastric cancer exclusively located in the upper third of the stomach. The theoretical therapeutic necessity of dissecting lymph nodes at each lymph node station was evaluated based on the therapeutic index calculated by multiplying the frequency of metastasis at each station and the 5-year survival rate of patients with metastasis to that station. Results The 5-year overall survival rate (95% confidence interval) was 72.9% (65.5–80.3). The metastatic rates at #4d and #12a were very low (0.99% and 0.006%, respectively), and those at #5 and #6 were zero, and therapeutic indices for #4d, #5, #6 and #12a were zero. On the other hand, the most frequent metastatic station was #3, followed by #1, #2 and #7 (overall metastatic rate > 12%), which was consistent with the order of the therapeutic indices. Conclusions Considering the nodal stations that need to be dissected, proximal gastrectomy would be the choice and oncologically safe for patients with T2/T3 proximal gastric cancer.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Proximal gastrectomy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Proximal gastric cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Therapeutic effect</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yoshikawa, Takaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Otsuki, Sho</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamagata, Yukinori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Morita, Shinji</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Katai, Hitoshi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nishida, Toshirou</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yoshiaki, Takaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Gastric Cancer</subfield><subfield code="d">Springer-Verlag, 2002</subfield><subfield code="g">22(2019), 5 vom: 18. Feb., Seite 1029-1035</subfield><subfield code="w">(DE-627)SPR009286586</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:5</subfield><subfield code="g">day:18</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:1029-1035</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10120-019-00938-8</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">2019</subfield><subfield code="e">5</subfield><subfield code="b">18</subfield><subfield code="c">02</subfield><subfield code="h">1029-1035</subfield></datafield></record></collection>
|
| author |
Yura, Masahiro |
| spellingShingle |
Yura, Masahiro misc Proximal gastrectomy misc Proximal gastric cancer misc Therapeutic effect Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer |
| authorStr |
Yura, Masahiro |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR009286586 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer Proximal gastrectomy (dpeaa)DE-He213 Proximal gastric cancer (dpeaa)DE-He213 Therapeutic effect (dpeaa)DE-He213 |
| topic |
misc Proximal gastrectomy misc Proximal gastric cancer misc Therapeutic effect |
| topic_unstemmed |
misc Proximal gastrectomy misc Proximal gastric cancer misc Therapeutic effect |
| topic_browse |
misc Proximal gastrectomy misc Proximal gastric cancer misc Therapeutic effect |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Gastric Cancer |
| hierarchy_parent_id |
SPR009286586 |
| hierarchy_top_title |
Gastric Cancer |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR009286586 |
| title |
Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer |
| ctrlnum |
(DE-627)SPR009350497 (SPR)s10120-019-00938-8-e |
| title_full |
Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer |
| author_sort |
Yura, Masahiro |
| journal |
Gastric Cancer |
| journalStr |
Gastric Cancer |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
txt |
| container_start_page |
1029 |
| author_browse |
Yura, Masahiro Yoshikawa, Takaki Otsuki, Sho Yamagata, Yukinori Morita, Shinji Katai, Hitoshi Nishida, Toshirou Yoshiaki, Takaki |
| container_volume |
22 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Yura, Masahiro |
| doi_str_mv |
10.1007/s10120-019-00938-8 |
| author2-role |
verfasserin |
| title_sort |
oncological safety of proximal gastrectomy for t2/t3 proximal gastric cancer |
| title_auth |
Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer |
| abstract |
Background It remains unclear whether total gastrectomy is necessary for patients with proximal T2/T3 gastric cancer. To explore the oncological safety of proximal gastrectomy for proximal T2/T3 gastric cancer, in this study, we evaluated the metastatic rates in and the therapeutic effect of dissection of key distal lymph node stations that are usually excluded in proximal gastrectomy. Methods In this study, we examined 202 patients seen between January 2000 and December 2012, who underwent total gastrectomy with lymph node dissection (D1/D1+/D2; 2/17/183) and was pathologically diagnosed as T2/T3 gastric cancer exclusively located in the upper third of the stomach. The theoretical therapeutic necessity of dissecting lymph nodes at each lymph node station was evaluated based on the therapeutic index calculated by multiplying the frequency of metastasis at each station and the 5-year survival rate of patients with metastasis to that station. Results The 5-year overall survival rate (95% confidence interval) was 72.9% (65.5–80.3). The metastatic rates at #4d and #12a were very low (0.99% and 0.006%, respectively), and those at #5 and #6 were zero, and therapeutic indices for #4d, #5, #6 and #12a were zero. On the other hand, the most frequent metastatic station was #3, followed by #1, #2 and #7 (overall metastatic rate > 12%), which was consistent with the order of the therapeutic indices. Conclusions Considering the nodal stations that need to be dissected, proximal gastrectomy would be the choice and oncologically safe for patients with T2/T3 proximal gastric cancer. |
| abstractGer |
Background It remains unclear whether total gastrectomy is necessary for patients with proximal T2/T3 gastric cancer. To explore the oncological safety of proximal gastrectomy for proximal T2/T3 gastric cancer, in this study, we evaluated the metastatic rates in and the therapeutic effect of dissection of key distal lymph node stations that are usually excluded in proximal gastrectomy. Methods In this study, we examined 202 patients seen between January 2000 and December 2012, who underwent total gastrectomy with lymph node dissection (D1/D1+/D2; 2/17/183) and was pathologically diagnosed as T2/T3 gastric cancer exclusively located in the upper third of the stomach. The theoretical therapeutic necessity of dissecting lymph nodes at each lymph node station was evaluated based on the therapeutic index calculated by multiplying the frequency of metastasis at each station and the 5-year survival rate of patients with metastasis to that station. Results The 5-year overall survival rate (95% confidence interval) was 72.9% (65.5–80.3). The metastatic rates at #4d and #12a were very low (0.99% and 0.006%, respectively), and those at #5 and #6 were zero, and therapeutic indices for #4d, #5, #6 and #12a were zero. On the other hand, the most frequent metastatic station was #3, followed by #1, #2 and #7 (overall metastatic rate > 12%), which was consistent with the order of the therapeutic indices. Conclusions Considering the nodal stations that need to be dissected, proximal gastrectomy would be the choice and oncologically safe for patients with T2/T3 proximal gastric cancer. |
| abstract_unstemmed |
Background It remains unclear whether total gastrectomy is necessary for patients with proximal T2/T3 gastric cancer. To explore the oncological safety of proximal gastrectomy for proximal T2/T3 gastric cancer, in this study, we evaluated the metastatic rates in and the therapeutic effect of dissection of key distal lymph node stations that are usually excluded in proximal gastrectomy. Methods In this study, we examined 202 patients seen between January 2000 and December 2012, who underwent total gastrectomy with lymph node dissection (D1/D1+/D2; 2/17/183) and was pathologically diagnosed as T2/T3 gastric cancer exclusively located in the upper third of the stomach. The theoretical therapeutic necessity of dissecting lymph nodes at each lymph node station was evaluated based on the therapeutic index calculated by multiplying the frequency of metastasis at each station and the 5-year survival rate of patients with metastasis to that station. Results The 5-year overall survival rate (95% confidence interval) was 72.9% (65.5–80.3). The metastatic rates at #4d and #12a were very low (0.99% and 0.006%, respectively), and those at #5 and #6 were zero, and therapeutic indices for #4d, #5, #6 and #12a were zero. On the other hand, the most frequent metastatic station was #3, followed by #1, #2 and #7 (overall metastatic rate > 12%), which was consistent with the order of the therapeutic indices. Conclusions Considering the nodal stations that need to be dissected, proximal gastrectomy would be the choice and oncologically safe for patients with T2/T3 proximal gastric cancer. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER |
| container_issue |
5 |
| title_short |
Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer |
| url |
https://dx.doi.org/10.1007/s10120-019-00938-8 |
| remote_bool |
true |
| author2 |
Yoshikawa, Takaki Otsuki, Sho Yamagata, Yukinori Morita, Shinji Katai, Hitoshi Nishida, Toshirou Yoshiaki, Takaki |
| author2Str |
Yoshikawa, Takaki Otsuki, Sho Yamagata, Yukinori Morita, Shinji Katai, Hitoshi Nishida, Toshirou Yoshiaki, Takaki |
| ppnlink |
SPR009286586 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s10120-019-00938-8 |
| up_date |
2024-07-04T01:41:46.708Z |
| _version_ |
1803610810444939264 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR009350497</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20201124064157.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10120-019-00938-8</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR009350497</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10120-019-00938-8-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Yura, Masahiro</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Oncological safety of proximal gastrectomy for T2/T3 proximal gastric cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background It remains unclear whether total gastrectomy is necessary for patients with proximal T2/T3 gastric cancer. To explore the oncological safety of proximal gastrectomy for proximal T2/T3 gastric cancer, in this study, we evaluated the metastatic rates in and the therapeutic effect of dissection of key distal lymph node stations that are usually excluded in proximal gastrectomy. Methods In this study, we examined 202 patients seen between January 2000 and December 2012, who underwent total gastrectomy with lymph node dissection (D1/D1+/D2; 2/17/183) and was pathologically diagnosed as T2/T3 gastric cancer exclusively located in the upper third of the stomach. The theoretical therapeutic necessity of dissecting lymph nodes at each lymph node station was evaluated based on the therapeutic index calculated by multiplying the frequency of metastasis at each station and the 5-year survival rate of patients with metastasis to that station. Results The 5-year overall survival rate (95% confidence interval) was 72.9% (65.5–80.3). The metastatic rates at #4d and #12a were very low (0.99% and 0.006%, respectively), and those at #5 and #6 were zero, and therapeutic indices for #4d, #5, #6 and #12a were zero. On the other hand, the most frequent metastatic station was #3, followed by #1, #2 and #7 (overall metastatic rate > 12%), which was consistent with the order of the therapeutic indices. Conclusions Considering the nodal stations that need to be dissected, proximal gastrectomy would be the choice and oncologically safe for patients with T2/T3 proximal gastric cancer.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Proximal gastrectomy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Proximal gastric cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Therapeutic effect</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yoshikawa, Takaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Otsuki, Sho</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamagata, Yukinori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Morita, Shinji</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Katai, Hitoshi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nishida, Toshirou</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yoshiaki, Takaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Gastric Cancer</subfield><subfield code="d">Springer-Verlag, 2002</subfield><subfield code="g">22(2019), 5 vom: 18. Feb., Seite 1029-1035</subfield><subfield code="w">(DE-627)SPR009286586</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:5</subfield><subfield code="g">day:18</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:1029-1035</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10120-019-00938-8</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">2019</subfield><subfield code="e">5</subfield><subfield code="b">18</subfield><subfield code="c">02</subfield><subfield code="h">1029-1035</subfield></datafield></record></collection>
|
| score |
7.400549 |